Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for lifetime management in younger patients with aortic stenosis.
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...
Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...
In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...
MarketBeat on MSN
Edwards Lifesciences Q2 earnings call highlights
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH Edwards Lifesciences (NYSE:EW) reported ...
Late Wednesday, a U.S. Food and Drug Administration panel recommended that Edwards Lifesciences (NYSE:EV) transcatheter aortic valve replacement procedure be approved for patients with high risk to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results